HIV and liver diseases: Recent clinical advances

Clinics in Liver Disease

Volumn 9, Issue 4, 2005, Pages 647-666

  Cengiz, Cem ^a   Park, James S ^a   Saraf, Neeraj ^a   Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CLEVUDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; ERYTHROPOIETIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; INDINAVIR; INTERFERON; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TELBIVUDINE; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DNA REPLICATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; ERADICATION THERAPY; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FATTY LIVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; GILBERT DISEASE; HEMATOLOGIC DISEASE; HEMOLYSIS; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIPID STORAGE; LIPOATROPHY; LISTERIA MONOCYTOGENES; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TOXICITY; LIVER TRANSPLANTATION; MENTAL DISEASE; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PANCREATITIS; PNEUMOCYSTIS JIROVECI; RECURRENCE RISK; REVIEW; RISK FACTOR; SEROCONVERSION; SEROLOGY; SIDE EFFECT; STEATOSIS; THROMBOCYTOPENIA; TOXOPLASMA GONDII; VIRUS STRAIN; VOMITING; WEIGHT REDUCTION; WILD TYPE;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER TRANSPLANTATION; RIBAVIRIN;

EID: 26044468242     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2005.07.009     Document Type: Review

References (97)

1. K.E. Sherman, S.D. Rouster, and R.T. Chung Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross sectional analysis of the US adult AIDS Clinical Trials Group Clin Infect Dis 34 2002 831 837
2. Y. Benhamou, M. Bochet, and V. Di Martino Liver fibrosis progression in human immunodeficiency virus infection and hepatitis C virus coinfected patients Hepatology 30 1999 1054 1058
3. R. Romeo, M.G. Rumi, and M.F. Donato Hepatitis C is more severe in drug users with human immunodeficiency virus infection J Viral Hepat 7 2000 297 301
4. Y. Benhamou, V. Di Martino, and M. Bochet Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfected patients: impact of protease inhibitor therapy Hepatology 34 2001 283 287
5. M. Puoti, R. Bruno, and V. Soriano Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome AIDS 18 2004 2285 2293
6. J. Garcia-Samaniego, M. Rodriguez, and J. Berenguer Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C Am J Gastroenterol 96 1 2001 179 183
7. I. Bica, B. McGovern, and R. Dhar Increasing mortality in end stage liver disease in patients with human immunodeficiency virus infection Clin Infect Dis 32 2001 492 497
8. T.L. Wright, H. Hollander, and X. Pu Hepatitis C in HIV infected patients with and without AIDS: prevalence and relationship to patient survival Hepatology 20 1994 1152 1155
9. A. Monto, L.M. Dove, and K.H. Seal HIV-HCV coinfected patients followed prospectively for a mean of 4.2 years, have similar rates of death or cirrhosis compared to HCV mono-infected patients Hepatology 40 4 2004 1212A
10. G. Greub, B. Ledergerber, and M. Battegay Clinical progression, survival, and immune recovery during anti retroviral therapy in patients with HIV-1 and hepatitis c virus coinfection: the Swiss HIV Cohort Study Lancet 357 2000 1800 1805
11. M.S. Sulkowski, R.D. Moore, and S.H. Mehta Hepatitis C and progression of HIV disease JAMA 288 2002 199 206
12. M. Bonacini, and M. Puoti Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues Arch Intern Med 160 2000 3365 3373
13. R.T. Chung, J. Anderson, and P. Volberding Peginterferon alfa -2a plus ribavirin versus interferon alfa 2a plus ribavirin for chronic hepatitis C in HIV coinfected persons N Engl J Med 351 2004 451 499
14. F. Carrat, F. Bani-Sadr, and S. Pol Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial JAMA 292 2004 2839 2848
15. F.J. Torriani, M. Rodriguez-Torres, and J.K. Rockstroh Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
16. T.N. Kakuda, and K. Brinkman Mitochondrial toxic effects and ribavirin Lancet 357 2001 1802 1803
17. D.T. Dieterich, and J.L. Spivak Hematological disorders associated with hepatitis C virus infection and their management Clin Infect Dis 37 2003 533 541
18. th Conference on Retroviruses and Opportunistic Infections. Boston, February 11, 2003
19. L.E. Taylor, T. Costello, and E. Alt Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus coinfected individuals AIDS 16 2002 1700 1701
20. M. Shim, I. Khaykis, and J. Park Low physician referral rates and high no-show rates are major barriers to HCV therapy among patients coinfected with HCV and HIV Hepatology 40 4 2004 A386
21. National Institute of Health Consensus Development Conference Statement Management of hepatitis C: 2002 Hepatology 36 5 2002 S3 S20
22. P. Trimoulet, D. Neau, and B. Le bail Intrahepatic HCV RNA loads in 37 HIV-HCV coinfected patients with controlled HIV infections J Med Virol 67 2002 143 151
23. C. Uberti-Foppa, A. De Bona, and G. Morsica Pretreatment of chronic active hepatitis C in patients coinfected with HIV and HCV reduces the hepatotoxicity associated with subsequent antiretroviral therapy J Acquir Immune Defic Syndr 33 2003 146 152
24. W.M. Lee Hepatitis B virus infection N Engl J Med 337 1997 1733 1745
25. G.M. McQuillan, T.R. Townsend, and H.A. Fields Seroepidemiology of hepatitis B virus infection in the United States. 1976 to 1980 Am J Med 87 3A 1989 5S 10S
26. R.P. Beasley Hepatitis B virus: the major etiology of hepatocellular carcinoma Cancer 61 1988 1942 1956
27. R.E. Solomon, M. VanRaden, and R.A. Kaslow Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection Am J Public Health 80 12 1990 1475 1478
28. J.F. Colin, D. Cazals-Hatem, and M.A. Loriot Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men Hepatology 29 1999 1306 1310
29. C.L. Thio, E.C. Seaberg, and R. Skolasky HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) Lancet 360 2002 1921 1926
30. D.T. Dieterich Human immunodeficiency virus and liver: lessons learned and still to be learned Semin Liver Dis 23 2 2003 107 114
31. V. Thibault, Y. Bbenhamou, and C. Seguret Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus J Clin Microbiol 37 1999 3013 3016
32. G.V. Papatheodoridis, E. Dimou, and V. Papadimitropoulos Nucleoside analogues for chronic hepatitis B: Antiviral efficacy and viral resistance Am J Gastroenterol 97 2002 1618 1628
33. P. Marcellin, T.T. Chang, and S.G. Lim Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816
34. R. de Franchis, A. Hadengue, and G. Lau EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version) J Hepatol 39 Suppl 1 2003 S3 S25
35. P. Angus, R. Vaughan, and S. Xiong Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV DNA polymerase Gastroenterology 125 2003 292 297
36. Y. Benhamou, M. Bochet, and V. Thibault Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label study Lancet 358 2001 718 723
37. C. Delaugerre, A.G. Marcelin, and V. Thibault Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine Antimicrob Agents Chemother 46 2002 1586 1588
38. M. Nunez, M. Perez-Olmeda, and B. Diaz Activity of tenofovir on hepatitis B virus replication in HIV-coinfected patients failing or partially responding to lamivudine AIDS 16 2002 2352 2354
39. S. Callens, A. De Roo, and R. Colebunders Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir J Infect 47 2003 262 263
40. M.B. Ristig, J. Crippin, and J.A. Aberg Tenofivir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-a and lamivudine therapy have failed J Infect Dis 186 2002 1844 1847
41. Y. Benhamou, R. Tubiana, and V. Thibault Tenofivir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus N Engl J Med 348 2003 177 178
42. W.G. Cooksley, T. Piratvisuth, and S.D. Lee Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen positive chronic hepatitis B J Viral Hepat 10 2003 298 305
43. H.L. Janssen, M. van Zonneveld, and H. Senturk Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 9454 2005 123 129
44. R. Rodriguez-Rosado, J. Garcia-Samaniego, and V. Soriano Hepatotoxicity after introduction of highly active antiretroviral therapy AIDS 12 1998 1256
45. M.S. Sulkowski, D.L. Thomas, and R.E. Chaisson Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis B or C virus infection JAMA 283 2000 74 80
46. M. Nunez, R. Lana, and J.L. Mendoza Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy J Acquir Immune Defic Syndr 27 2001 426 431
47. Reisler R., Servoss J.C., Sherman K.E., et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials: ACTG Liver Diseases Focus Group [abstract 43]. Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires (Argentina): 2001. p. 94
48. F.W. Wit, G.J. Weverling, and J. Weel Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy J Infect Dis 186 2002 23 31
49. M. Saves, S. Vandentorren, and V. Daucourt Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA) AIDS 13 1999 F115 F121
50. P. Chariot, I. Drogou, and I. de Lacroix-Szmania Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion J Hepatol 30 1999 156 160
51. M. John, C.B. Moore, and I.R. James Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy AIDS 15 2001 717 723
52. K. Boubaker, M. Flepp, and P. Sudre Hyper-lactatemia and antiretroviral therapy: the Swiss HIV Cohort Study Clin Infect Dis 33 2001 1931 1937
53. V. Falco, D. Rodriguez, and E. Ribera Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature Clin Infect Dis 34 2002 838 846
54. A. Johnson, A. Ray, and J. Hanes Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase J Biol Chem 276 2001 40847 40857
55. S. Staszewski, C. Katlama, and T. Harrer A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naïve subjects AIDS 12 1998 F197 F209
56. M.S. Saag, A. Sonnerborg, and R.A. Torres Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults AIDS 12 1998 F203 F209
57. D. Boxwell, H. Haverkos, and S. Kukich Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures-worldwide, 1997-2000 MMWR Morb Mortal Wkly Rep 49 2001 1153 1156
58. P. Cahn, M. Johnson, and R. Nusrat Hepatic safety with nevirapine (NVP) and two nucleosides in patients with advanced HIV infection, from a placebo (PBO)-controlled clinical endpoint trial (1090) AIDS 14 2000 511
59. S. Becker Liver toxicity in epidemiological cohorts Clin Infect Dis 38 Suppl 2 2004 49 55
60. D.T. Dieterich, P.A. Robinson, and J. Love Drug-induced liver injury associated with the use of non-nucleoside reverse-transcriptase inhibitors Clin Infect Dis 38 Suppl 2 2004 80 89
61. F. van Leth, P. Phanuphak, and K. Ruxrungtham Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study Lancet 363 2004 1253 1263
62. E. Martinez, J. Blanco, and J.A. Arnaiz Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy AIDS 15 2001 1261 1268
63. M. Sulkowski, D. Thomas, and S. Mehta Hepatotoxicity associated with nevirapine and efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections Hepatology 35 2002 182 189
64. Dieterich D.T., Stern J., Robinson P., et al. Analyses of 4 key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4 + levels, hepatitis B&C seropositivity and baseline liver function tests. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires (Argentina), July 8-11, 2001
65. A. Aceti, C. Pasquazzi, and B. Zechini Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection J Acquir Immune Defic Syndr 29 2002 41 48
66. C. Michelet, A. Ruffault, and V. Sebille Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients Antimicrob Agents Chemother 45 2001 3393 3402
67. C.L. Cooper, M.A. Parbhakar, and J.B. Angel Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus Clin Infect Dis 34 2002 1259 1263
68. M.S. Sulkowski, S.H. Mehta, and R.E. Chaisson Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir AIDS 18 2004 2274 2284
69. A. Carr, and D.A. Cooper Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor Lancet 349 1997 995 996
70. M. John, J. Flexman, and M.A. French Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12 1998 2289 2293
71. A. Carr, K. Samaras, and D.J. Chisholm Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance Lancet 351 1998 1881 1883
72. B.J. Glasgow, K. Anders, and L.J. Layfield Clinical and pathologic findings of the liver in the acquired immunodeficiency syndrome (AIDS) Am J Clin Pathol 83 1985 582 588
73. L.A. Guarda, M.A. Luna, and J.L. Smith Jr Acquired immunodeficiency syndrome: postmortem findings Am J Clin Pathol 81 1984 549 557
74. T. Piratvisuth, P. Siripaitoon, and H. Sriplug Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus J Gastroenterol Hepatol 14 1999 146 149
75. C. Katlama Consequences for the management of cytomegalovirus AIDS 10 Suppl 1 1996 43 46
76. R.R. Razonable, and C.V. Paya Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts Expert Rev Anti Infect Ther 2 2004 27 41
77. M. Costa-Mattioli, C. Allavena, and A.S. Poirier Prolonged hepatitis A infection in an HIV-1 seropositive patient J Med Virol 68 2002 7 11
78. S. Ida, N. Tachikawa, and A. Nakajima Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection Clin Infect Dis 34 2002 379 385
79. A.L. Ridolfo, S. Ruscoli, and S. Antinori Persisting HIV-1 replication triggered by acute hepatitis A infection Antivir Ther 5 2000 15 17
80. J. Xiang, S. Wuenschmann, and D.J. Diekema Effect of coinfection with GB virus C (hepatitis G virus) on survival among patients with HIV infection N Engl J Med 345 2001 707 714
81. Xiang J., George S.L., Wuenschmann S, et al. GBV-C infection inhibits CCR5 and CXCR4 HIV strains, and alters chemokine and cytokine gene expression in PBMC cultures. Presented at the Conference on Retroviruses and Opportunistic Infections. Boston, February 12, 2003
82. th Conference on Retroviruses and Opportunistic Infections. Seattle (WA), February 24-28, 2002
83. D.E. Mosier, and F.V. Chisari GB virus C and mortality from HIV infection N Engl J Med 346 2002 377 379
84. M. Duong, J.M. Petit, and L. Piroth Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy J Acquir Immune Defic Syndr 27 2001 245 250
85. K. Agarwal, M. Fiel, and A.J. Uriel Correlation of insulin resistance with steatosis and fibrosis in hepatitis C and HIV coinfection: Cross-sectional analysis of 101 patients Hepatology 40 Suppl 1 2004 348A
86. C. Hadigan, C. Corcoran, and N. Basgoz Metformin in the treatment of HIV lipodystrophy syndrome JAMA 284 2000 472 477
87. T. Saint-Marc, and J.L. Touraine Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy AIDS 13 1999 1000 1002
88. M.C. Gelato, D.C. Mynarcik, and J.L. Quick Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study J Acquir Immune Defic Syndr 31 2002 163 170
89. A. Calmy, B. Hirschel, and D. Hans Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy AIDS 17 2003 770 772
90. E. Martinez, M.A. Garcia-Viejo, and J.L. Blanco Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy Clin Infect Dis 31 2000 1266 1273
91. A. Carr, J. Hudson, and J. Chuah HIV protease inhibitor substitution in patients with lipodystrophy: a randomised controlled, open-label, multi-centre study AIDS 15 2001 1811 1822
92. A. Carr, C. Workman, and D.E. Smith Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial JAMA 288 2002 207 215
93. Jury of the International Consensus Conference on Indications of Liver Transplantation Consensus statement on indication for liver transplantation: Paris. June 22-23, 1993 Hepatology 20 1994 63S
94. A. Tzakis, M.H. Cooper, and J.S. Dummer Transplantation in HIV-positive patients Transplantation 49 1990 354 358
95. S. Moreno, J. Fortun, and C. Quereda Liver transplantation in HIV infected recipients Liver Transpl 11 2005 76 81
96. S. Norris, C. Taylor, and P. Muiesan Outcomes of liver transplantation in HIV infected individuals: The impact of HCV and HBV infection Liver Transpl 10 2004 1271 1278
97. M.V. Ragni, S.H. Belle, and K. Im Survival of human immunodeficiency virus-infected liver transplant recipients J Infect Dis 188 2003 1412 1420